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ABSTRACT 
Cystic fibrosis is a life-shortening genetic disease that affects the respiratory, digestive and 
reproductive systems. Though it manifests a variety of symptoms, it is most notably characterized 
by chronic pulmonary infections that ultimately lead to respiratory failure and premature death. 
Recent research has focused on developing inhaled aerosol antibiotics to treat such infections; 
however, current formulations use saline liquid carriers that are unable to fully disperse the drugs 
throughout the lungs, as the surface tension of saline is much higher than the surface tension of the 
airway liquid surface. Given that certain lipid surfactants are capable of lowering the surface 
tension of aqueous solutions, our hypothesis is that a surfactant-based liquid carrier could greatly 
improve pulmonary drug dispersion and efficacy to better treat lung infections. Previous work both 
in vitro and in a small group of cystic fibrosis patients has led to the creation of an optimized, self-
dispersing inhaled carrier formation that significantly enhances aerosolized drug spreading under 
very specific, laboratory conditions. The aims of this project are to develop an in vivo imaging 
model to assess pulmonary drug dispersion, and then to use this model to determine if our 
surfactant-based formulation also improves drug dispersion in a murine model. To model drug 
dispersal in the lungs, we instilled BL/6 mice with a combination of fluorescent dye and either 
water or surfactant, and then measured the amount of fluorescence in different planar regions of 
the lungs. We then calculated the ratio of fluorescence in the peripheral lung regions to the total 
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fluorescence in the lungs, and used this to compare the mice instilled with water/dye solution to 
those instilled with surfactant/dye solution (p = 0.0287). Public health significance: Our results 
suggest that our candidate surfactant significantly increases pulmonary drug dispersion in the 
murine airways, and future studies are necessary to confirm these findings in human subjects. We 
hope that future research can build upon our early results to create an optimal inhaled antibiotic 
capable of fully eradicating CF-related pulmonary infections and improving patient outcomes.  
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1.0  INTRODUCTION 
Cystic fibrosis (CF) is an incurable genetic disease that affects the respiratory, digestive and 
reproductive systems. Although CF manifests a variety of symptoms, it is most notably 
characterized by chronic pulmonary infections that ultimately lead to respiratory failure and 
premature death. CF is caused by a defect in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene, which encodes an ion channel protein responsible for regulating chloride 
and thiocyanate transport across lung epithelial cells (1). To date, over 1,900 disease-causing 
mutations have been characterized in the CFTR protein, resulting in a wide-spectrum of disease 
severity (2). However, one mutation -- ∆F508 –accounts for about 70% of CF cases, and results in 
the premature degradation of the CFRT protein (3).  
Though the CFTR protein is also found in the liver, pancreas, skin, and reproductive and 
digestive tracts, the most serious complications of CF arise from the malfunctioning of CFTR in 
the lungs. When CFTR is functioning properly, negatively charged chloride and thiocyanate ions 
are actively transported out of lung epithelial cells into the surrounding airway surface liquid 
(ASL) – the thin layer of fluid that exists between the airway epithelial cell apical surface and the 
mucus layer. It also acts to regulate the epithelial sodium channel protein, ENac, through an 
unknown mechanism to prevent sodium and water flow out of the ASL and into the cell epithelium. 
When CFTR is malfunctioning, however, ion movement out of the cell is blocked, and ion 
movement into the cell by ENac is unregulated (4). There are several theories regarding how these 
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changes result in the clinical manifestation of CF, but the most popular suggests that the altered 
ion concentration leads to dehydration of the airway epithelium (5). In brief, it is thought that in 
order to balance the flow of sodium ions into the respiratory cell epithelium when ENac is 
unregulated, water also flows into the cell by osmosis. As the water is drawn into the cell and out 
of the ASL, it depletes the volume of the ASL and exposes the lung cilia to the mucus layer. 
Because the cilia cannot function properly in the viscid environment, they cannot effectively clear 
mucus from the airways, resulting in the accumulation of a thick mucus layer that then clogs the 
small airways and promotes bacterial infection (5). These bacteria thrive in the thickened, nutrient-
rich mucus, which shelters them from immune cells and antibiotics. Over time, these chronic 
infections permanently alter the lung architecture, making infections increasingly difficult to treat. 
1.1 CYSTIC FIBROSIS EPIDEMIOLOGY AND PATIENT BURDEN 
Despite the lethal nature of CF, the disease is surprisingly common in the Caucasian population, 
and is considered to be one of the most widespread life-shortening genetic diseases (6). Currently, 
it is estimated that around 30,000 Americans live with CF, with another 2,500 new cases occurring 
every year (6,7).  
Cystic fibrosis usually manifests within a year of birth, but onset may be delayed until 
adolescence with severe complications continuing until death. Early in the disease progression, the 
lungs of CF patients develop thick, sticky mucus that blocks the small airways and allows for 
persistent bacterial infections. The resulting chronic inflammation leads to severe lung damage 
and lung disease, with respiratory failure accounting for roughly 85% of CF-associated mortality 
(7). In the pancreas, the thickened mucus builds up to block movement of digestive enzymes into 
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the small intestine, resulting in pancreatic damage, pancreatitis, malabsorption, poor growth, 
diabetes, osteoporosis and in older patients, exocrine pancreatic insufficiency (Reviewed in 
[8],9,10). Additionally, thickened mucus in the liver can change bile viscosity and result in 
cirrhosis and liver disease – another leading cause of CF-associated mortality (11).  
Though recent advances in therapeutics have prolonged the average lifespan of CF patients 
from early childhood to nearly 40 years, they have also drastically increased the burden of 
treatment for adults living with CF. At minimum, patients are required to take daily pancreatic 
replacement enzymes, inhaled/nebulized antibiotics, and oral anti-inflammatory drugs, as well as 
partake in daily airway clearance regimens and vitamin therapy (12). A recent study reported that 
adult CF patients spend an average of 108 minutes a day fulfilling their treatment regimens, and 
that because of this, many patients opt not to complete all of the recommended therapies (12). 
Another study focusing on the financial burden to patients found that the average annual out-of-
pocket costs for CF management are around $16,000USD per patient, with life-time costs 
exceeding $300,000USD (13). Because of the disease’s severity and increasing complex and 
expensive treatment requirements, the goal of current research is to design new, more effective 
treatment options that reduce the daily burden on CF patients and increase their quality of life. 
1.2 CHRONIC BACTERIAL INFECTION 
In a healthy respiratory system, there exists a balance of microbiota: while the upper respiratory 
tract is colonized by a variety of commensal microorganisms, the lower respiratory tract contains 
very low levels of microorganisms, protected by the ability of the lung cilia to expel trapped 
bacteria in the mucus layer before reaching the lungs. However, as this mechanism is hindered in 
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cystic fibrotic lungs, common pathogens of the UTR—such as Staphylococcue aureus and 
Haemophilus influenza—are able to colonize the lungs at an early age (14). Over time, 
Pseudomonas aeruginosa (and to a lesser degree, Burkholeria cepacia) dominates the other 
pathogens to establish thick biofilms and large colonies that are able to subvert the host immune 
system and evade antibiotics. In fact, bacteria living in biofilms can have dramatically increased 
resistance to antibiotics in comparison to the same bacterial species living in planktonic conditions. 
Persistent infection with P. aeruginosa leads to chronic activation of the inflammatory response, 
with the ultimate consequence of severe immune-mediated tissue damage (15).  
Though less common than P. aeruginosa, Klebsiella pneumoniae is also known to infect 
CF lungs and cause serious alveolar damage. Like P. aeruginosa, K. pneumoniae is a gram-
negative, multidrug-resistant pathogen; however, unlike P. aeruginosa, K. pneumoniae can cause 
mortality, with a death rate as high as 50% for Klebsiella bacteremia and pneumonia (16). 
Additionally, some species of K. pneumoniae can produce K. pneumoniae carbapenemases (KPCs) 
– enzymes capable of inactivating carbapenem-class antibiotics, which are often used to treat MDR
P. aeruginosa (17). As the gene responsible for conferring this ability is located on a mobile
genetic element, dissemination of the KPC phenotype to other bacterial species poses a significant 
threat (18). Though not yet widespread, KPC-producing P. aeruginosa have been identified (19), 
and multiple studies have reported KPC-producing K. pneumoniae infection in CF patients (18,20). 
treatment options that reduce the daily burden on CF patients and increase their quality of life. 
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1.3 CURRENT TREATMENTS 
Traditional treatments for CF-associated pulmonary infections rely on orally- and IV-administered 
antibiotics. Because these methods cannot directly target the lungs, the drugs must be delivered in 
very high doses that may result in serious side effects (21). In order to directly target the lungs and 
bypass some of these issues, recent research has focused on developing inhaled aerosol antibiotics. 
Currently, there are only two aerosol antibiotics approved for the treatment of CF in the US – 
TOBI® (tobramycin) and CAYSTON® (azethronam). However, while these drugs are superior to 
their oral and IV-counterparts, they are not without flaws. Multiple studies have shown that while 
inhaled drugs disperse well in unobstructed airways, they often fail to reach infection sites in 
obstructed airways (22-24). The thickened mucus and blocked airways characteristic of CF and 
other obstructive pulmonary diseases prevent uniform aerosol deposition, resulting in high local 
drug concentrations in the central airways and low to none in the peripheral airways (25,26). As 
such, these types of treatments may act to enhance drug-resistance selection, likely due to their 
inability to consistently deliver full therapeutic doses to infection sites (21,27). 
A major hindrance to the dispersion of current inhaled antibiotic formulations –including 
both TOBI® and CAYSTON®--is the use of saline as a liquid carrier (28,29). Due to simple 
capillary forces, aerosolized droplets deposited onto the ASL will only spread if their surface 
tension is lower than that of the ASL (23); however, saline has a higher surface tension than the 
ASL, ~70dyn/cm compared to ~35-60dyn/cm (30,31). Therefore, theoretically, an aerosol liquid 
carrier with a surface tension lower than that of the ASL will be able to better transport drugs along 
the ASL and to regions of reduced ventilation.  
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1.4 SURFACTANTS 
Surfactants are amphiphilic molecules capable of lowering the surface tension of aqueous solutions 
by adsorbing to liquid interfaces (32). They can be of natural origin, such as lecithin, or of synthetic 
origin, such as sodium dodecyl sulfate. Synthetic surfactants can be further classified as anionic, 
cationic, non-ionic, or zwitterionic, depending on the charge of their polar head groups. In the 
human lungs, natural pulmonary surfactant is required for pulmonary compliance and adsorbs to 
the air-water interface of alveoli to lower the surface tension during inhalation and expiration (33). 
Research stemming from the success of infant surfactant replacement therapy (SRT), in which 
exogenous pulmonary surfactant is instilled into the lungs of premature infants born with 
insufficient amounts, suggests that instilled natural surfactants can be used to create surface tension 
gradients capable of moving fluid from areas of low surface tension to areas of high surface tension 
(34-36). It is possible that these convective flows, termed Marangoni flows, can also be used to 
move drugs from areas of high surfactant concentration (low surface tension) to areas of low 
surfactant concentration (high surface tension), resulting in more uniform aerosolized drug 
spreading (37). In support of this theory, several animal studies have concluded that instilled drug 
delivery dispersion and/or efficacy can be increased by the addition of surfactant carriers 
(34,38,39). Of particular relevance to our work is a study by Veen et al., which showed that the 
addition of natural pulmonary surfactant to instilled tobramycin solution increased survival of mice 
infected with Klebsiella pnuemoniae (38). To date, however, little research has been conducted to 
investigate the possible benefits of surfactant-based drug carriers in aerosolized antibiotics.  
Capstone FS-3100, the surfactant tested in this study, is a synthetic, non-ionic fluorinated 
surfactant that is approved for industrial uses. In contrast to natural pulmonary surfactant, FS-3100 
has been specifically engineered to maximize surface tension reduction. Though no surfactant-
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based nebulized drugs currently exist, evidence suggests that non-ionic surfactants are generally 
less toxic and hemolytic, cause less irritation to cellular surfaces, and more easily maintain near-
neutral pH when compared to their anionic and cationic counterparts (reviewed in 40). The most 
noteworthy characteristic of non-ionic surfactants, however, is their ability to self-assemble into 
vesicles –termed niosomes—that are analogous to liposomes and are capable of transporting 
aqueous solutes and penetrating mucoid biofilms (41).  
Fluorinated surfactants, or fluorosurfactants, are a special class of synthetic surfactants that 
have multiple fluorocarbons coating their tail groups. Unlike hydrocarbon surfactants, they are not 
amphiphilic, and are intrinsically much more effective at lowering surface tension (42). This 
quality is partly due to the high electronegativity and low polarizability of the fluorine atom, which 
reduces London dispersion forces (43). Additionally, because the carbon-fluorine bond is so 
strong, fluorosurfactants are much more chemically and thermally stable than other types of 
surfactants (43). Collectively, these traits make FS-3100 an ideal candidate surfactant for a self-
dispersing pulmonary drug carrier.  
1.5 IMAGING 
The IVIS® Spectrum in vivo imaging system from Caliper Life Sciences is a cutting-edge optical 
imaging platform capable of performing noninvasive, real-time visualization of fluorescence and 
bioluminescence in small animals. In this study, we use the IVIS® SpectrumCT, which has the 
additional capacity to perform X-ray imaging and 3D small animal surface reconstruction via a 
high-speed microCT system. Only those features used in this study will be further discussed below. 
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    For fluorescent optical imaging, the IVIS® system can detect and quantify all commonly 
used fluorophores, with the capacity to differentiate between multiple fluorescent reporters at 
once, as well as correct for tissue autofluorescence. A 150 Watt quartz tungsten halogen lamp 
provides the excitation light source, which is then fed through a filter to an optical switch that 
either directs the light to the top of the chamber (epi-illumination) or to the bottom of the stage 
(transillumination) (44). While transillumination setting allows for deeper tissue 
penetration and reduced autofluorescence, it uses a directed light source that only images at 
precise x,y locations; therefore, epi-illumination is preferred when imaging over a large area. To 
prevent autofluorescent signaling during epi-illumination, black paper or tape can be used to 
cover parts of the animal and manually block signaling. Additionally, using a fluorophore 
in the far-red region can help reduce autofluorescence, as animal tissue can fluoresce when 
excited with low-wavelength light.  
   To measure fluorescent signal, the user must first specify a region(s) of interest (ROI). 
These regions can be selected automatically by the software or manually by the user using 
pre-formed shapes, or drawn by the user free-hand. The software then quantifies the fluorescent 
signal within that area. Radiance, or emission radiance, is calculated as the “number of photons 
per second that leave a square centimeter of tissue and radiate into a solid angle of one 
steradian”: (p/sec/cm2/sr) (44). However, because the fluorescent signal detected depends not 
only on the fluorescence in the sample, but also on the intensity of the incident excitation light, 
the system must correct for this and instead displays fluorescence in radiant efficiency, or 
total emission radiance divided by incident excitation radiance: (p/sec/cm2/sr)/(µW/cm2) (44). 
In addition to total radiant efficiency, the software also displays average radiant efficiency, or 
the sum of the radiance inside of the ROI/number of ROI pixels; the standard deviation of the 
radiant efficiency; and the minimum and maximum values of the radiant efficiency within the 
ROI.  
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1.6 PRIOR RESEARCH 
Extensive research by our colleagues here at the University of Pittsburgh and at Carnegie Mellon 
University has led to the creation of an optimized, self-dispersing, inhaled surfactant carrier 
formation that significantly enhances aerosolized drug spreading under very specific, laboratory 
conditions. With the results of their studies, we were able to build our murine model and test the 
candidate surfactant formulation to determine if it also increases aerosolized drug spreading in 
vivo. The following is a brief summary of their journey to determine the best candidate surfactant 
for use in our animal studies.  
1.6.1 Preliminary data: in vitro 
Before they could determine a candidate surfactant for our group to test, our colleagues conducted 
a series of preliminary in vitro studies investigating the post-deposition spreading of surfactant-
based aerosols on complex surfaces analogous to the ASL. In their first study, surfactant/dye and 
saline/dye solutions were delivered via aerosol onto mucin solutions and HBE cell cultures derived 
from both CF and non-CF lungs (23). For every surface tested—including the cell cultures derived 
from CF lungs—they found substantial increases in dispersion using surfactants over saline (23). 
Other preliminary in vitro studies showed that, 1) while surfactant-induced surface tension 
gradients do drive initial spreading, the final spread of the formulation is determined more by the 
physical characteristics of the surfactant (45); and 2) SRT surfactant formulations are not ideal 
candidates for enhancing pulmonary drug dispersion (46). Together, these studies developed all of 
the experimental techniques required for the candidate surfactant screening research later on.  
 10 
1.6.2 Preliminary data: in vivo  
After reaching the above conclusions, our colleagues conducted a pilot imaging study to determine 
if surface tension enhanced dispersion could be measured in the cystic fibrotic lungs of 8 human 
patients (47). Using radiolabeled particles as a drug surrogate and a nuclear medicine gamma 
camera, they 1) successfully measured aerosol deposition and post-deposition spreading in the 
obstructed lungs, and 2) showed that, in a very small group of patients, natural pulmonary 
surfactant formulations increased aerosol medication dispersal.  
1.6.3 Candidate surfactant studies  
Armed with the preliminary in vitro and in vivo data, our colleagues performed multiple studies to 
“determine how carrier composition and physicochemical properties can be used to control the 
post-deposition spreading of inhaled medications and to develop an optimized self-dispersing 
aerosol carrier” (S. Garoff, T. Corcoran, and T. Przybycien, 25 February 2011, grant proposal). 
Through this work, they determined the ideal spreading compositions and aersolization parameters 
for three different classes of candidate surfactants: SRT-based phospholipid aggregate 
formulations (48); simple, synthetic oligomeric surfactants, such as Tyloxapol and SDS (32, 
49,50); and low surface tension perfluorinated surfactants, such as FS-3100 (49). After extensively 
investigating all candidate surfactants, our colleagues chose Capstone FS-3100 for testing by our 
murine model. 
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2.0  SPECIFIC AIMS 
Previous in vitro work by our colleagues has resulted in the determination of an optimal surfactant 
formulation that improves pulmonary drug dispersion under very specific, laboratory conditions. 
Because these in vitro methods cannot fully account for the complexities of human airway 
dynamics, animal studies are a necessary next step towards developing inhaled aerosolized 
medications. Therefore, the aim of this project is to determine if our candidate surfactant-based 
drug carrier formulation improves drug dispersion and efficacy in a murine model of Klebsiella 
pneumoniae infection over standard inhaled drug formulations. Additionally, these animal studies 
will allow us to use bacterial infection and recovery as a clinical outcome measure, which future 
human studies will be unable to assess.  
2.1 AIM 1:  ASSESS THE LETHALITY OF AEROSOLIZED KLEBSIELLA 
PNEUMONIAE IN MICE. 
a. Determine the growth characteristics of Klebsiella strains in specified media in order to 
elucidate optimal harvest time for infection studies and to determine mathematical 
equations for bacterial concentration calculations.  
 
b. Determine the infection characteristics and lethality of aerosolized Klebsiella in BL/6 
mice.   
 
c. Directly image progressing infection with bioluminescent Klebsiella using in vivo 
imaging methods to better elucidate disease course, if applicable. 
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2.2 AIM 2: DEVELOP AN IN VIVO MODEL TO CHARACTERIZE PULMONARY 
DRUG DISPERSION IN MICE USING FLUOROPHORES AS A DRUG SURROGATE. 
a. Determine optimal method and conditions of dye solution delivery to optimize 
fluorescent imaging.  
  
b. Develop method to quantify and compare drug dispersion using the IVIS® in vivo 
imaging system.  
 
c. Apply method to determine if addition of surfactant improves drug dispersion in the lung 
compared to control solution. 
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3.0  MATERIALS AND METHODS 
3.1 BIOSAFETY 
All aerosol experiments were performed in a class III biological safety cabinet within the 
Aerobiology Suite in the University of Pittsburgh Regional Biocontainment Laboratory (RBL). As 
the SpectrumCT IVIS® imaging system is located in a ABSL3 suite within the RBL, all animal 
work was conducted at ABSL3 conditions in a class II biosafety cabinet. Powered air purifying 
respirators (PAPRs) were worn for respiratory protection, and Vesphene IIse (diluted 1:128, Steris 
Corporation, cat. #646101) was used for disinfection. 
14 
3.2 ANIMAL INFORMATION 
All animal procedures were approved by the Institutional Animal Care and Use Committee 
(IACUC) at the University of Pittsburgh, under protocol number 14084237.  
Mice: C57 BL/6 and B6 Albino mice were purchased from Charles Rivers and Jackson 
Labs and fed alfalfa-free chow (Envigo:2920X) upon arrival for at least one week prior to imaging 
to minimize autofluorescence during imaging. For temperature monitoring during infection 
studies, mice were implanted with temperature chips (BMDS: IPTT-300) prior to infection. For 
infection studies, mice were monitored at least twice daily for temperature, weight loss, and 
changes in behavior and appearance. Mice used in infection studies were euthanized when 
moribund or at study end point. All mice were euthanized by carbon dioxide intoxication followed 
by cervical dislocation to confirm euthanasia.  
3.3 BACTERIAL STRAINS AND GROWTH CONDITIONS 
Luciferase-expressing K. pnuemoniae strain Kp Xen-39 (ATCC 93A 5370) was obtained from Dr. 
Min Wu and the University of North Dakota. Xen-39 was originally made by Caliper Life Sciences 
(now part of PerkinElmer) and is specifically designed for use with their IVIS® imaging system. 
K. pnuemoniae (ATCC 43816 serotype 2) was kindly provided by Dr. Janet S. Lee (University of
Pittsburgh School of Medicine). 
All bacteria were stored in -80°C as 25% glycerol stocks. Overnight cultures were prepared 
by streaking a Luria-Bertani (LB) agar (BD Difco™, cat. #244520) plate with a small quantity of 
frozen bacterial stock. The plates were then incubated for 16-24 hours at 37°C. Several colonies 
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were then selected from each plate and re-suspended in 2.5ml of growth media. After adjusting 
the optical density to 0.06 to .08 at 600 nm, 0.5 ml of the bacteria solution was added to 24.5ml of 
growth media in a 125ml filter top flask. Cultures were incubated for 4 hours at 37°C with shaking. 
Kp Xen-39 was cultured in LB broth; ATCC 43816 was cultured in both LB broth and trypticase 
soy broth (TSB) (BD Difco™, cat. #211825). 
3.4 FLUOROPHORES 
Fluorescent carboxylic acid dye Alexa Fluor® 647 and 750 were obtained from Thermo Fischer 
Scientific. SPHERO™ Sky Blue fluorescent microparticles were obtained from Spherotech, Inc 
(Lakeforest, IL). The excitation and emission maximums for all fluorophores are summarized in 
Table 1. 
Table 1. Excitation and Emission Maximums of Fluorophores 




SPHERO™ Sky Blue microparticles 675 700 
Alexa Fluor® 647 carboxylic acid dye 650 665 
Alexa Fluor® 750 carboxylic acid dye 749 775 
3.5 GROWTH ASSAY 
Prior to any experiments, growth curves were established for both Klebsiella strains to determine 
log-phase growth. Briefly, bacterial cultures were prepared as previously described in either LB 
or TSB. These 25ml cultures (in 125ml filter top baffled Erlenmeyer flasks) were placed on a 200 
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rpm shaker at 37°C for up to six hours. At every hour starting at time zero, 300 µl of each culture 
were removed for measurement: 200 µl were placed in a clear 96-well plate for OD reading at 
600nm; 100 µl were serially diluted out to 10e-11 and dilutions were plated in triplicate on LB 
plates. For luciferase-expressing Kp Xen-39, and additional 200 µl were removed at each hour for 
bioluminescent reading. Using the resulting optical density and colony-forming-unit growth 
curves, non-linear regression was used to determine bacterial concentration. 
3.6 AEROSOLS 
3.6.1 Klebsiella aerosols 
Bacteria aerosols were performed using a Collison 3-jet nebulizer (CH Technologies, Westwood, 
NJ) and a rodent, whole-body chamber controlled by the AeroMP exposure system (Biaera 
Technologies, Hagerstown, MD). Each experiment consisted of one to five runs, ten minutes in 
length followed by a five-minute air wash. On the day of aerosol, 25ml Klebsiella cultures were 
harvested after 4 hours of growth in LB broth, at 37°C with shaking at 200rpm. The optical density 
(OD) at 600nm was taken, and then the sample was diluted to the desired starting bacterial 
concentration based on derived equations. Serial dilutions were then made by diluting 2.5ml of the 
culture in an additional 22.5ml of LB broth, out to 1:10,000 depending on the experiment. Aerosol 
runs proceeded from lowest bacterial concentration to highest bacterial concentration.   
Aerosol samples were collected using an all-glass impinger (AGI), each prepared with 
10ml of LB broth and 40 µl of antifoam. To determine aerosol concentrations, tenfold dilutions of 
all AGI samples were made out to 10e-7, and dilutions of all nebulizer samples out to 10e-9 using 
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1X Phosphate Buffered Saline (PBS). A multichannel pipette was used to “drop” 10 µl of five 
successive dilutions onto an LB plate, and the “drops” were then allowed to drip vertically along 
the plate such that no dilutions mixed. All samples were plated in triplicate and incubated overnight 
at 37°C. Dilutions with 10-100 colonies were counted and used to determine bacterial titers.  
3.6.2 Fluorescent drug surrogate aerosols 
Fluorescent drug surrogate aerosols were performed using an Aeroneb nebulizer (Aerogen) and a 
rodent, nose-only chamber controlled by the AeroMP exposure system. Each experiment consisted 
of two to six runs, ten to twenty minutes in length. 0.5 ml of SPHERO™ Sky Blue microspheres 
were diluted in 9.5 ml of either deionized water or 1% Capstone FS-3100 (DuPont, Wilmington, 
DE); or 0.5 mg of Alexa Fluor® 750 were suspended in 500 µl DMSO, then added to 19.5 ml of 
either deionized water or 1% FS-3100. Sham aerosols were performed first without animals to 
determine particle size and spray factor. Aerosol samples were collected using an AGI, each 
prepared with 10ml of deionized water and 40 µl of antifoam. A Next-Generation Impactor (MSP 
Corp., Shoreview, MN) and Aerodynamic Particle Sizer (TSI, Shoreview, MN) were used to 
determine aerosol particle size (Figure 1). Aerosols with animals were performed using the same 
parameters as sham aerosols, four to five animals at a time, with imaging immediately post aerosol 
completion.   
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Figure 1. Particle size of aerosolized Sky Blue Microspheres and Alexa Fluor® 750 
Particle size, measured as mass median aerodynamic diameter (MMAD), of Alexa Fluor® 750 diluted in both 
deionized water (blue/purple) and FS-3100 surfactant (red/green). Particle size is approximately the same for both 
water and FS-3100, about 2 µm.  
3.7 IMIT INSTILLATION 
Intubation-mediated intratracheal (IMIT) instillation protocol was adapted from Lawrenz, et al. 
(51). First, 5 mg of Alexa Fluor® 750 were suspended in 500 µl DMSO, then added to 2ml of 
deionized water, FS-3100, or isotonic saline for a final concentration of 2mg/ml. BL/6 mice were 
anesthetized using 75mg/kg ketamine and 1.0mg/kg dexmedetomidine. Only one mouse was done 
at a time to ensure adequate anesthesia and minimal time between delivery of dye and imaging. 
After mice were sedated, 10 µL of 2% of lidocaine was applied to the throat using a micropipette, 
and mice were allowed to rest for 5 minutes to allow lidocaine to reach full effect. At this point, 
mice were imaged on the IVIS® to determine pre-exposure levels of fluorescence. Next, dye/water 
or dye/surfactant solutions were pre-loaded into a 250 µl gas-tight precision glass syringe fitted 
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with a 22G long blunt needle. First, 150 µl of air were drawn up into the syringe, followed by 10, 
25, or 50 µl of either dye/water or dye/surfactant, followed by additional air to equal 200 µl in 
total. The mouse was placed on the intubation platform and secured by hooking its incisors with 
an O-ring to the intubation platform. The platform was then raised to a 45° incline. Using a cotton 
applicator, the tongue was retracted and a wire-guided, 20G 1” catheter was inserted through the 
mouth to a 10 mm depth into the trachea. To confirm successful intubation, a 1/16” tubing 
containing 20 µl of Coomassie Brilliant Blue dye was secured to the catheter; if the dye migrated 
rapidly back and forth (in response to the animal’s breathing), intubation was successful. If 
successful intubation could not be confirmed, no more than two more attempts were made in a 
single session to prevent causing trauma to the mouse. Finally, the glass syringe was inserted 
through the catheter to 1” depth, and the contents slowly dispensed into the lungs in a single fluid 
motion. The needle and catheter were then removed and mice imaged immediately on the IVIS®. 
3.8 IVIS IMAGING 
All imaging took place within the RBL rodent suit under ABSL-3 conditions due to the location 
of the IVIS®. Mice imaged post-aerosol were first anesthetized using an isoflurane/oxygen, with 
continued dosing during imaging; mice imaged post-IMIT were only given a light isoflurane dose 
during imaging to sustain ketamine/dexmedetomidine anesthesia. Using the excitation and 
emission wavelengths that best complemented each reagent, the mouse whole body was then 
imaged on an In Vivo Imaging System SpectrumCT (IVIS®; PerkinElmer) to measure fluorescent 
signal. All image reconstruction and imaging analysis was done on a separate computer using 
Living Image® 4.5.2 software (Perkin Elmer) that is designed for use with the IVIS®. In most 
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cases, only the IVIS® 2D imaging functions were used; however, several animals also underwent 
3D fluorescence imaging tomography (FLIT) to confirm dye localization. In the case of FLIT, 
animals’ abdomens were shaved prior to imaging to increase FLIT signal, as recommended by 
PerkinElmer. 
3.9 REGION OF INTEREST ANALYSIS 
Using the Living Image 4.5.2 software, two oval regions of interest (ROI) were drawn around the 
mouse lungs to measure total and central lung fluorescence (Figure 2). Total lung fluorescence 
was measured by the larger, outer oval region; central lung fluorescence was measured by the 
smaller, inner oval region; the peripheral fluorescence was calculated as the difference between 
the two regions. The ratio of peripheral fluorescence to total fluorescence (P/T) was then used to 
determine the extent of dispersion from central to peripheral lung regions. Within the context of 
this study, the terms “central” and “peripheral” are only used to describe the 2D regions illustrated 
in Figure 2, and do not refer to any particular anatomical regions of the lungs. The central region 
corresponds roughly to the dye solution deposition site, and the peripheral region to those sites 
farthest away from the initial deposition site. Fluorescence was measured by radiant efficiency, in 
units (p/sec/cm2/sr)/(µW/cm2). ROI size and shape were maintained across all images (Table 2), 
and all images were adjusted to the same fluorescent scale to ensure accurate visual comparison. 
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Figure 2. Region of Interest (ROI) Diagram 
Location of the two ROI drawn around mouse lungs. Total lung fluorescence is measured by the outer ROI, which 
encompasses the entire lung region. Central lung fluorescence is measured by the inner ROI, which encompasses only 
the central airways. Peripheral lung fluorescence is then calculated by subtracting the central fluorescence from the 
total fluorescence. 
Table 2. ROI circumference and total area, in pixels 
Circumference Area 
Outer ROI 408 8.403e04 
Inner ROI 131 2.611e04 
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3.10 STATISTICAL ANALYSIS 
GraphPad Prism® 6 was used to create all graphs and equations, and to perform two-sided T-tests 
comparing the P/T ratios between water and surfactant treatment groups. P<0.05 was considered 
statistically significant. Non-linear regression analysis was used to create the bacterial 
concentration equations due to the non-linear relationship between OD600 and bacterial 
concentration.  
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4.0  RESULTS 
4.1 AIM 1: ASSESS THE LETHALITY OF AEROSOLIZED KLEBSIELLA 
PNUEMONIAE IN MICE 
Before beginning any experiments, we first needed to determine the growth characteristics of our 
Klebsiella pneumoniae (Kp) strains (Figure 3). At every hour out to six hours, the optical density 
was recorded at 600 nm (Figure 3A,B). For the luciferase-expressing Kp Xen-39 strain, the hourly 
luminescence was also recorded (Figure 3C). However, for reasons that will be discussed later, we 
eventually had to replace the luminescent Kp Xen-39 strain with the highly pathogenic, Kp ATCC 
43816 strain. Because we had been growing Kp Xen-39 in Luria-Bertaini (LB) broth, but trypticase 
soy broth (TSB) was recommended for ATCC 43816, we decided to compare the growth rates of 
the ATCC 43816 in both media (Figure 3B). Though the bacteria did seem to grow slightly better 
in TSB, we did not find the difference to be significant. Therefore, even though all initial 












Figure 3. Growth characteristics of Klebsiella pneumoniae strains 
Optical density at 600nm vs time in hours: (A) Two replicates of Xen-39 grown in LB broth; (B) ATCC 43816 grown 












While performing each growth curve, I also plated serial dilutions of the hourly samples, 
and used those to calculate colony-forming-units per milliliter at each time point (CFUs). I then 
used non-linear regression analysis to compare optical density to measured cell counts, and derived 
an equation to calculate concentration based on optical density (Figure 4, Table 3). These equations 
were used in later aerosol exposures to determine the ideal initial bacterial concentrations to deliver 
a specific inhaled dose. 
Figure 4. Calibration curve to convert optical density at 600nm to bacterial concentration in CFU/ml 
(A) Xen-39 and (B) ATCC 43816. Logarithmic transformation was performed to best fit the data.
A Xen-39 B ATCC 43816 
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Table 3. Equations generated from calibration curve 
Kp Strain Equation 
Xen-39 Y= -4920 + 4928.19 / (1+10^ ( (-1.307 – X)*2.417) ) 
ATCC 43816 Y = -23387 + 23397.22 / (1+10^ ( (-0.07382 – X)*28.10) ) 
Y = Log10(bacterial concentration in CFU/ml); X = OD@600nm 
In order to determine the lethality of the Kp Xen-39 strain, BL/6 mice were exposed to 
increasing log10 doses of aerosolized Kp Xen-39 using a Collison 3-jet nebulizer and a rodent, 
whole-body exposure chamber. Fifty mice were infected in five groups of ten, with Group 1 
representing the lowest dose of Kp and Group 5 representing the highest dose. Starting 
concentration in the nebulizer was approximated using the standard curve calculated for Kp Xen-
39, and final inhaled doses were calculated by plating serial dilutions of aerosol samples and then 
adjusting for spray factor. Mice were then monitored twice daily for seven days post-exposure for 
changes in weight, temperature, natural and provoked behavior, and appearance. Unfortunately, 
none of the groups showed significant weight loss during the monitoring period (Figure 5A), nor 
did they show any other signs of illness (data not shown). Given that Kp Xen-39 expresses 
luciferase and was developed for imaging with the IVIS®, we attempted to directly visualize the 
Kp in the mouse lungs. Three mice from each infection group were imaged in the IVIS® on days 
0, 1, 2 and 4 post-infection; however, no luminescence was measured at any time point (data not 
shown). To confirm these results, we performed a smaller, but similar experiment using only five 
mice and a very high dose of Kp Xen-39, 1.5 x 108 CFUs, and still did not observe any signs of 
illness or luminescence (data not shown).  
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 Given that Kp Xen-39 did not result in observable illness or luminescence, we decided to 
switch to Kp ATCC 43816 – a known pathogenic strain in BL/6 mice – based on the 
recommendation of Dr. Janet Lee (who also provided the strain). After a preliminary test using 
only five mice and a dose of 9 x 105 CFU resulted in the death of all five mice within 72 hours 
(data not shown), we proceeded with another lethality assay similar to the one performed with Kp 
Xen-39. Twenty mice were split into four groups of five and infected with increasing log10 doses 
of aerosolized ATCC 43816 and monitored for six days post-infection, by which time all mice had 
succumbed to illness (Figure 5B). The initial dose was calculated using the standard curve, and all 
final doses by serial dilution plating of the nebulizer samples.  
The euthanasia criteria employed was based on a combination of factors meant to assess 
febrile illness and weight loss in mice (Appendix A). A combined score of 16 or higher must result 
in euthanasia, and any animal showing a sustained temperature below 34°C (2 or more consecutive 
readings) or weight loss above 20% must also be euthanized promptly. Because none of the mice 
lost a significant amount of weight but all developed severe hypothermia (temperature below 
340C), time of euthanasia was determined by temperature in combination with significantly 
























Figure 5. Lethality Assay 
Fifty BL/6 mice were infected via aerosol with increasing log10 doses of Kp Xen-39. Animals were monitored twice-
daily for seven days post-infection for signs of illness, including weight change (A). Inhaled doses: Group 1 = 5.05 x 
103 CFU; 2 = 4.56 x104 CFU; 3 = 6.14 x 105 CFU; G 4 = 5.67 x 106 CFU; 5 = 3.87 x 107 CFU. Twenty BL/6 mice 
were infected via aerosol with increasing log10 doses of Kp ATCC 43816 and monitored twice-daily for six days 
post-infection, at which point all animals succumbed to illness (B). Inhaled doses: Group 1 = 6.06 x 103 CFU; 2 = 
6.00 x 104 CFU; 3 = 3.03 x 105 CFU; 4 = 4.33 x 106 CFU. Temperature change (C) was the only defining characteristic 
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4.2 AIM 2: DEVELOP AN IN VIVO MODEL TO CHARACTERIZE PULMONARY 
DRUG DISPERSION IN MICE USING FLUOROPHORES AS A DRUG SURROGATE 
4.2.1 Dispersion assay: Aerosolized microspheres 
In the first attempt to visualize lung dispersion, two different sizes of Spherotech SPHERO™ Sky 
Blue fluorescent microspheres in the nanometer range were delivered via aerosol with a vibrating 
mesh nebulizer. Prior to animal experiments, microspheres were mixed with either deionized water 
or Capstone FS-3100 surfactant to determine aerosol characteristics in the presence of surfactant 
(data not shown). Aerosol particle size was determined using a Next-Generation Impactor with 
direct sampling from the aerosol chamber.  
In the first animal experiment, four BL/6 mice were exposed to aerosolized Sky Blue 
microspheres in size 0.1-0.3 µm mixed with surfactant or water, and then imaged immediately 
after using the IVIS® (Figure 6). Because the Sky Blue microspheres are not one of the 99 pre-
programmed fluorescent reporters in the Living Image 4.5.2 software database, we had to manually 
set the excitation and emission peak wavelengths for the software to read. Based on the data 
provided by Spherotech, we chose an excitation peak around 675nm and an emission peak around 
700nm. After two separate attempts using the same conditions resulted in no measurable 
fluorescence, we concluded that the skin and fur could be obscuring the signal and decided to 
image the lungs directly. The mice were euthanized promptly, and imaged with their chest cavities 
opened and lungs exposed; the lungs were then removed and imaged separately (data not shown). 
As we were still unable to measure any fluorescence, we considered the possibility that the 
microspheres were clogging the nebulizer and decided to perform another two aerosols using a 
smaller size of Sky Blue microspheres, 0.04-0.09 µm (data not shown). After reiterating the same 
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process only to achieve the same results, we concluded that the fluorescent microspheres were not 
the ideal drug surrogate for this study and considered other fluorophores.  
Figure 6. Representative IVIS® images 
Mouse exposed to aerosolized Sky Blue microspheres, size = 0.1-0.3 µm diluted in water (right), and Alexa Fluor® 
750 diluted in water (left). Red = fluorescent signal.  
4.2.2 Dispersion assay: Aerosolized fluorescent dye 
In a second attempt to visualize lung dispersion, the fluorescent microspheres were replaced with 
Alexa Fluor® 750 carboxylic acid dye. Before the initiation of this study, our group had attempted 
to visualize lung dispersion using Alexa Fluor® 647 with little success; however, because photon 
scattering is reduced at longer wavelengths and Alexa Fluor® 750 is farther red-shifted, we 
hypothesized that it would result in more sensitive fluorescent measurements than the Alexa 
Fluor® 647.  
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As with the microspheres, the Alexa Fluor® 750 dye was first mixed with either deionized 
water or Capstone FS-3100 surfactant to determine aerosol characteristics in the presence of 
surfactant (Figure 1). Once it was confirmed that the addition of surfactant did not alter the particle 
size, we continued with animal experiments.  
We performed a total of three aerosols with four BL/6 mice each; in each experiment, two 
mice were exposed to the water/dye solution, and two were exposed to the surfactant/dye solution. 
Immediately following exposure, mice were anesthetized and imaged on the IVIS® using the pre-
programmed Living Image software emission and excitation peak wavelengths for Alexa Fluor® 
750: 775nm and 800nm respectively. Just as with the microspheres, little or no fluorescence was 
observed in the lungs in any animal exposed (Figure 6B); even when the lungs were removed and 
imaged separately, no difference in fluorescence was observed between groups (data not shown). 
Given that the whole body images only showed fluorescence in the upper neck and throat region, 
we concluded that either 1) aerosolization using the capabilities we have available cannot deliver 
a sufficient volume of the solution deep enough into the lungs to produce a measurable signal with 
the IVIS®, or 2) the time difference between exposure and imaging (between 20-30 minutes) due 
to transportation of the animals between different suits could be dampening the fluorescent signal. 
4.2.3 Dispersion assay: Intubation-mediated intratracheal instillation (IMIT) 
After multiple unsuccessful attempts to deliver the dye solution via aerosol, we decided to instead 
adopt an intubation-mediated intratracheal (IMIT) instillation method of delivery. In brief, mice 
are anesthetized using ketamine/dexmedetomidine, and placed on a platform raised to a 45° angle. 
A catheter fitted to a guide-wire is then inserted into the trachea; once the catheter is in place, the 
guide-wire is removed and replaced with a 20G blunt-end syringe needle that is loaded with 150µl 
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of air + 10-50µl of water/dye or surfactant/dye. In order to validate the procedure, several test runs 
were performed using Coomassie Brilliant Blue dye diluted in water. Mice were euthanized 
immediately after delivery and their lungs removed to confirm the presence of dye. Initially, we 
had intended to anesthetize mice using isoflurane alone; however, we realized during the test runs 
that the procedure was more time-intensive than the isoflurane allowed, so we altered the 
procedure to include anesthesia via ketamine/dexmedetomidine.  
In the first attempts using the IMIT procedure, we instilled 150µl of air + 50µl of dye/water 
or dye/surfactant solution into C57 BL/6 mice, and then allowed the mice to rest on the intubation 
platform at 45o for five minutes post-delivery before imaging (Figure 7). Due to an inexperience 
with the technique, only two out of twelve attempts were successful: one with water/dye solution, 
one with surfactant/dye solution. At this point in our study, we had not yet developed our model 
for measuring dye dispersion, so instead we measured the total lung fluorescence and the standard 
deviation of the lung fluorescence using the IVIS® ROI tool. (Table 4). Between the two groups, 
the standard deviation of the fluorescence intensity in the mouse instilled with water/dye solution 
was roughly 3X that of the standard deviation of the fluorescence intensity in the mouse instilled 
with surfactant/dye solution. Additionally, the range in fluorescence intensity in the mouse 
instilled with the water/dye solution was roughly 4X higher than the range of fluorescence intensity 
in the mouse instilled with surfactant/dye solution. Taken together, we believe this shows less 
uniformity in dye dispersion in the lungs of the mouse instilled with the water solution.  
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Figure 7. IMIT instillation with 50 µl of Alexa Fluor® 750 fluorescent dye solution 
Top: Before and 5 minutes after instillation with 50 µl of Alexa Fluor® 750 + water. Bottom: Before and after 
instillation with 50 µl of Alexa Fluor® 750 + FS-3100. ROI = Region of Interest (blue), indicates total fluorescence 
within region. All imaging conditions were the same in all images. 
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Water 8.88e09 2.16e08 3.19e08 2.26e09 
FS-3100 5.51e09 1.34e08 1.20e08 6.09e08 
Radiant Efficiency = (p/sec/cm2/sr)/(µW/cm2) 
After discussing this data with our colleagues, it was suggested that resting the mice on the 
incline for five minutes post-instillation before imaging could be altering our results by allowing 
gravity to increase dispersion. It was also suggested that 50 µl of dye solution may be flooding the 
lungs and preventing dispersion. With this advice, we altered our procedure to image the next set 
of C57 BL/6 mice immediately post-instillation, and reduced the instillation amount from 50µl to 
25µl of dye solution (Figure 8). CT scans of every other mouse instilled were performed using the 
IVIS® to confirm the localization of the fluorescent signal within the lung region (Figure 9). In 
the mice instilled with water/dye solution (n=10), there are more concentrated, brighter spots of 
fluorescence than in the mice instilled with surfactant/dye (n=11), suggesting less uniform 
distribution of the dye when diluted in water. In an attempt to quantify this difference, we 
developed a system to measure the fluorescence in the peripheral regions of the lungs using two 
different ROI for each mouse as illustrated in Figure 2. We then calculated the ratio of peripheral 
fluorescence to total fluorescence (P/T) to index the extent of pulmonary dispersion (Table 5). A 
two-sided T-test comparing the P/T ratios of mice instilled with water/dye to mice instilled with 
surfactant/dye resulted in a p-value of 0.0824. Though these results are not statistically significant, 






Figure 8. IMIT instillation with 25 µl of Alexa Fluor® 750 fluorescent dye solution 
Top: Representative images of mice instilled with 25 µl of Alexa Fluor® 750 + water (n=10). Bottom: Representative 
images of mice instilled with 25 µl of Alexa Fluor® 750 + FS-3100 (n=11). All imaging conditions were the same in 









Figure 9. 3D fluorescence imaging tomography (FLIT) of mice instilled with 25 µl of Alexa Fluor® 750 dye 
solution 
Top: Representative CT image of mouse instilled with 25 µl of Alexa Fluor® + water. Bottom: Representative CT 
image of mouse instilled with 25 µl of Alexa Fluor® + FS-3100.  
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Table 5. Fluorescence by region and P/T ratios of mice instilled with 25 µl of Alexa Fluor® 750 dye solution 
Total Central Peripheral P/T Ratio 
Water 1.92e09 1.25e09 6.78e08 35.24 
Water 2.04e09 1.02e09 1.01e09 49.71 
Water 3.25e09 2.24e09 1.02e09 31.31 
Water 1.39e09 6.50e08 7.36e08 53.07 
Water 7.76e08 3.29e08 4.48e08 57.66 
Water 1.27e09 5.85e08 6.81e08 53.81 
Water 9.88e08 4.57e08 5.31e08 53.70 
Water 1.56e09 7.67e08 7.94e08 50.86 
Water 2.85e09 1.96e08 8.91e08 31.27 
Water 2.00e09 1.18e08 8.18e08 41.00 
FS-3100 3.43e09 1.73e09 1.17e09 49.77 
FS-3100 3.56e09 2.17e09 1.38e09 38.87 
FS-3100 1.72e09 6.26e08 1.10e09 63.63 
FS-3100 1.62e09 7.53e08 8.62e08 53.37 
FS-3100 1.64e09 9.77e08 6.60e08 40.29 
FS-3100 1.79e09 7.78e08 1.02e09 56.64 
FS-3100 1.45e09 5.96e08 8.49e08 58.75 
FS-3100 3.25e09 1.63e09 1.63e09 50.00 
FS-3100 2.19e09 9.85e08 1.20e09 54.94 
FS-3100 3.65e09 1.39e09 2.26e09 61.98 
FS-3100 3.16e09 1.50e09 1.66e09 52.52 
Lung fluorescence measured in radiant efficiency, units (p/sec/cm2/sr)/(µW/cm2). 
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According to PerkinElmer, albino mice and nude mice are preferred for imaging with the 
IVIS® over black mice, as the black fur increases light scatter. Therefore, in an attempt to increase 
fluorescent signal, we performed the same procedure as above with eight B6 Albino mice. 
However, as the entire animal fluoresced bright red, we were unable to differentiate any signal in 
the lungs from the rest of the body (data not shown).   
Concerned that we were still flooding the mouse lungs with a 25 µl dose of dye solution, 
we lowered the dose to 10 µl of solution (Figure 10). Instilling such a small amount of liquid 
proved challenging, and many attempts resulted in little to no fluorescence in the lungs of the mice. 
CT scans of every other mouse instilled were performed using the IVIS® to confirm the 
localization of the fluorescent signal within the lung region (Figure 11). Only eight out of thirty-
two attempts resulted in measureable fluorescence, and a two-sided T-test comparing the P/T ratios 







Figure 10. IMIT instillation with 10 µl of Alexa Fluor® 750 fluorescent dye solution 
Top: Representative images of mice instilled with 10 µl of Alexa Fluor® 750 + water (n=3). Bottom: Representative 









Figure 11. 3D fluorescence imaging tomography (FLIT) of mice instilled with 10 µl of Alexa Fluor® 750 dye 
solution 
Top: Representative CT image of mouse instilled with 10 µl of Alexa Fluor® + water. Bottom: Representative CT 
image of mouse instilled with 10 µl of Alexa Fluor® + FS-3100.  
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Table 6. Fluorescence by region and P/T ratios of mice instilled with 10 µl of Alexa Fluor® 750 dye solution 
Total Central Peripheral P/T Ratio 
Water 6.23e08 2.82e08 3.42e08 58.81 
Water 1.24e09 6.92e08 5.52e08 44.35 
Water 8.88e08 4.38e08 4.50e08 50.71 
FS-3100 1.19e09 5.88e08 6.04e08 50.65 
FS-3100 1.09e09 5.61e08 5.24e08 48.31 
FS-3100 1.10e09 4.68e08 6.29e08 57.32 
FS-3100 2.05e09 8.80e08 1.17e09 57.01 
FS-3100 7.65e08 2.48e08 5.17e08 67.60 
Lung fluorescence measured in radiant efficiency, units (p/sec/cm2/sr)/(µW/cm2) 
Throughout our study, water was used as the control drug carrier because the surfactant, 
FS-3100, is diluted in water. However, a more clinically-relevant control carrier would be saline, 
as that is what most aerosolized drugs are diluted in. In our last experiment, we instilled one mouse 
with 25 µl of saline/dye solution and calculated the P/T ratio (Table 7). Though one mouse is not 
enough to make a statistical comparison, a visual assessment reveals a single, concentrated region 
of fluorescence similar to that seen in mice instilled with 25 µl of water/dye solution (Figure 12). 
In the future, we will perform experiments using both saline and water as control carriers.  
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Table 7. Fluorescence by region and P/T ratio of mouse instilled with 25 µl of Alexa Fluor® 750 dye diluted in 
isotonic saline 
Total Lung Central Lung Peripheral Lung P/T Ratio 
Saline 3.41e09 1.64e09 1.78e09 52.10 
Lung fluorescence measured in radiant efficiency, units (p/sec/cm2/sr)/(µW/cm2) 
Figure 12. IMIT instillation with 25 µl of Alexa Fluor® 750 fluorescent dye diluted in isotonic saline 
Black paper and tape were used to reduce autofluorescence. 
Given the very small sample sizes from both sets of mice instilled with different amounts 
of dye solution, we combined the P/T data from all twenty-nine successfully instilled mice (not 
including the two instilled with 50 µl of dye). The p-value from the two-sided T-test comparing 
the combined P/T ratios, p=0.0287, is statistically significant and supports our hypothesis that FS-
3100 increases pulmonary dispersion in a murine model.  
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5.0  DISCUSSION 
The development of inhaled aerosol antibiotics has transformed the management of cystic fibrosis-
related pulmonary infections. Aerosol antibiotics can deliver high local concentrations of drugs 
into the airways to directly target the sites of infection and reduce systemic toxicity. However, the 
efficacy of these drugs depends on their ability to deposit and spread in obstructed airways, and to 
do so in high enough doses to overcome the resistance mechanisms of the colonized bacteria. In 
order to enhance aerosolized drug spreading and efficacy, we propose using lipid surfactants as 
drug carriers. Saline, the current standard carrier, has a surface tension much higher than that of 
the airway surface liquid, and we believe this prevents its ability to fully disperse aerosolized drugs 
in the airways. Research associated with surfactant replacement therapies have hinted that instilled 
surfactants can be used to create surface tension gradients capable of driving pulmonary drug 
dispersion, but so far little work has been done to translate this into an inhaled antibiotic. With this 
in mind, we set out to determine if lipid surfactants can indeed increase pulmonary drug dispersion 
and efficacy in a murine model. 
In order to develop a model to characterize pulmonary drug dispersion, we first needed to 
characterize murine bacterial pneumonia so that we can eventually perform surfactant-augmented 
antibiotic treatment studies. We chose to use a Klebsiella pneumoniae model because the 
Klebsiella model has been used in previous murine studies of surfactant-enhanced tobramycin 
delivery (38).  
Initially, we had planned to use a bioluminescent strain of Klebsiella, Xen-39, for all of our 
bacteria experiments, believing that we would be able to directly image the bacterial infection in 
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the mouse lungs using the bioluminescent function of the IVIS®. However, not only were we 
unable to measure any luminescence in vivo, we were also unable to deliver a lethal dose to the 
mice using aerosolization. We were surprised by these results, given that a recent paper published 
by Tan et al. reported significant Xen-39 lethality and bioluminescence in C57BL/6 mice with an 
intranasally instilled dose of 10e5 CFUs (52). A literature review revealed several, older studies 
that reported significantly reduced virulence of some Klebsiella pneumoniae strains when 
aerosolized versus when administered by other routes of infection (53-56). Though none of these 
studies gave a reason for these findings, it is possible that some strains of Klebsiella pneumoniae 
are rendered less infectious when aerosolized, and that our Xen-39 is one of them. In order for a 
pathogen to be infectious via aerosol, it must 1) be able to withstand the harsh aerosolization 
conditions, and 2) remain infectious while airborne. Klebsiella is a gram-negative bacteria 
enveloped in a polysaccharide capsule, where it contains many of its virulence factors, including 
LPS and capsular antigens. Given that the different serotypes of Klebseilla vary significantly in 
the size and composition of their capsular polysaccharides (16), it could be that certain serotypes 
– of which Xen-39 may belong – are more susceptible to severe damage during aerosolization. It 
is also possible that the Xen-39 we acquired had simply been passaged too many time in culture 
and had become attenuated. Whatever the reason for the reduced pathogenicity of the Xen-39 
strain, in retrospect, we should have first tested the strain in a small set of mice before performing 
the large lethality study with 50 animals, and we will not repeat this mistake. 
Aerosolization of Kp ATCC 43816 resulted in 100% mortality in the BL/6 mice within 24 
hours at the highest dose of 4.33 X 106 CFU, and within 6 days at the lowest dose of 6.06 X 103 
CFU (Figure 5B). A literature review of other murine pneumonia models revealed that animals 
reaching internal temperatures below 32-34°C fail to recover, and instead rapidly deteriorate to 
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death within 24 to 48 hours (57-59). Because of this, we chose to euthanize all animals that reached 
an internal temperature below 34°C for two consecutive daily measurements. Interestingly, this 
seemed to be the only defining criteria for terminal illness, as none of the animals developed any 
other symptoms severe enough to warrant euthanasia (such as significant weight loss or physical 
symptoms). A subsequent literature review suggested that our finding may not be unusual, as other 
murine pneumonia models also reported no significant weight loss in terminally ill animals – only 
hypothermia and subdued behavior (57). However, employing this criterion alone for disease 
severity sacrifices sensitivity. Although the microchips are highly accurate, they can fall out or 
malfunction. Four of the twenty mice were removed from the study prior to reaching 34°C due to 
either chip malfunction or chip loss.  
A major limitation of our pneumonia model is that it is based only on observable, physical 
symptoms of live animals. In order to create a more accurate model of Kp induced pneumonia, we 
would need to serially sacrifice animals throughout the experiment and remove the lungs for assays 
such as histopathological examination, quantification of viable bacteria, and lipid peroxidation (to 
estimate extent of tissue damage). However, given that our end goal is not to characterize the 
bacterial pneumonia itself-- but to assess how drug efficacy changes with different drug carriers-- 
we believe our temperature-based model is sufficient.  
Ultimately, we determined that aerosolization of Kp ATCC 43816 results in 100% 
mortality within six days post-infection with doses as low as 103 CFU. We also determined that 
temperature monitoring is the best indicator of disease progression, as few mice developed any 
other typical symptoms of illness. These results will help us plan future antibiotic treatment studies 
and allow us to use disease progression and recovery as measurable outcomes of Klebsiella 
infection and surfactant-based antibiotic treatment.  
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We next focused on developing our image-based, pulmonary drug dispersion model. Using 
fluorescent dye as a tracer and drug surrogate, we developed a ready-to-use, in vivo model to 
characterize dispersion based on the ratio of fluorescence in peripheral lung regions to the 
fluorescence in the total lung region, denoted the P/T ratio (Figure 2). We then applied this model 
to show that our candidate surfactant carrier, FS-3100, increases pulmonary dispersion over water 
carriers when instilled into murine lungs. 
Through the model development process, we learned that aerosolization of fluorophores 
with the technologies available to us will not result in measurable fluorescent signal, and instead 
adopted the IMIT instillation technique of delivery. We believe that aerosol delivery failed because 
the system we used delivers the dye solution at a rate greater than six liters per minute, which may 
dilute the fluorophores above detection capacity.  
Though our initial goal was to deliver the fluorescent dye via aerosol, we are confident in 
our choice to use the IMIT instillation for our lung dispersion assays. Initial dispersion studies 
performed by our colleagues at Carnegie Mellon University assessed aerosolized FS-3100 
spreading deposited onto in vitro surfaces; our model represents a ‘more complex’ system that 
bridges the gap between those in vitro studies and the human airways. Several animal studies have 
shown that instilled liquid surfactant carriers can improve pulmonary drug distribution (34, 60) 
and increase animal survival when administered with an antibiotic (38, 61); however, most of these 
studies test natural, exogenous pulmonary surfactant and related synthetic surfactants approved for 
use in SRT (34,38, 60,61). To our knowledge, we are the first to explore the possible clinical uses 
of the industrial fluorosurfactant, FS-3100. Additionally, our method uses novel in vivo imaging 
techniques to visualize lung dispersion using fluorescent particles, where as all other pulmonary 
dispersion assays we found either require lung removal or use radiolabeled particles as drug 
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surrogates (22,60,62-64). Our model is therefore superior to these other methods because 1) it does 
not require surgery or subject euthanasia; 2) it does not require special waste disposal; and 3) the 
fluorophores used are non-toxic and more stable than radiolabeled particles.  
One limitation to this model is the use of murine lungs to model dispersion. Lung structure 
is a major factor contributing to inhaled particle deposition, and murine lungs differ significantly 
from human lungs; where human lungs have relatively symmetric, dichotomous branching patterns 
and two left lung lobes, murine lungs are strongly monopodial and only have one left lung lobe 
(65). Additionally, the small size of murine lungs makes instillation difficult and limits the physical 
range of possible droplet spreading. Now that we have successfully shown that FS-3100 increases 
pulmonary spreading in mice, however, we have grounds to use larger animals in future studies.  
Another limitation to our model is the use of healthy, non-obstructed lungs to model 
dispersion. Though several murine models of cystic fibrosis exist, they are not without significant 
flaws and are beyond the scope of this study. Future experiments will need to take into 
consideration how the surfactant will perform in obstructed airways; however, here we have used 
healthy lungs to develop an initial model. Our study demonstrates that a surfactant carrier can 
significantly increase pulmonary drug dispersion of a drug surrogate when instilled into murine 
lungs and that this model is potentially useful for evaluating surfactants to improve pulmonary 
drug delivery. 
5.1 PUBLIC HEALTH SIGNIFICANCE 
The continued development of novel treatments for cystic fibrosis has increased the median life-
expectancy for those living with CF to around 40-years of age, but some 80% of patients still die 
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from complications arising from persistent lung infections. Inhaled antibiotics are frequently 
prescribed for the treatment of such infections, yet their efficacy is limited by their ability to 
adequately reach infection sites in obstructed airways, and to do so in high enough concentrations 
to fully eradicate the microbes. In such cases, the chronic delivery of sub-par antibiotic doses to 
some parts of the lungs may actually act to increase selection of antibiotic resistant strains in those 
areas. The emergence of multi-resistant pathogens in CF patients is well documented, and several 
studies have shown that infection with such strains significantly worsens patient outcomes (66-
69). Additionally, while inhaled antibiotics have proved more effective than traditional methods 
of delivery in suppressing infection, to date, none have been able to fully eradicate CF pathogens, 
nor have any been found to be consistently effective. Thus, it is imperative that we continue to 
develop better antibiotics for treating CF-associated lung infections.  
Our study demonstrates that a surfactant carrier can significantly increase pulmonary 
dispersion of a drug surrogate when instilled into murine lungs. More research is needed to 
determine if this ability will hold when the surfactant is inhaled, or if it will translate to increased 
drug efficacy in obstructed human airways. We hope that future research can build upon our early 
results to create an optimal inhaled antibiotic capable of fully eradicating CF-related pulmonary 
infections and improving patient outcomes.  
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APPENDIX: MOUSE OBSERVATION SCORING SYSTEM 
 
Weight loss: 0-4.9% = 1; 5-9.9% = 2; 10-14.9% = 3; 15.1-20% = 4; > 20% = euthanize promptly 
 
Temperature: 34-39.9degC = 1; 40.0-40.9degC = 2; 41.0-41.9degC = 3; >41.9 = 4; <34 =  
 
euthanize promptly  
 
Natural Behavior: Normal = 1; less peer interaction = 2; little peer interaction, less mobile = 3;  
 
no peer interaction, vocalization, restless or still = 4 
 
Provoked Behavior: Normal = 1; subdued but normal when stimulated = 2;  
 
subdued even when stimulated = 3; unresponsive even when stimulated = 4 
 
Appearance: Normal = 1; reduced grooming = 2; dull/rough coat or ocular/mucosal discharge =  
 
3; hunched, piloerection, or respiratory distress = 4 
 
Total Score:   5-9: Normal 
     
10-15: Clinical illness; increase observations to every six hours 
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